1-4 of 4
Nicoletta Anzalone
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Relevance of MYD88 L265P Mutation and Interleukin-10 Level in Cerebrospinal Fluid of Patients with Both Newly Diagnosed and Relapsed Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Andres JM Ferreri, MD, Teresa Calimeri, MD PhD, Paolo Lopedote, MD, Ilaria Francaviglia, Rita Daverio, MD, Chiara Iacona, Cristina Belloni, BD, Sara Steffanoni, MD, Elena Anghileri, MD, Angelo Diffidenti, Annamaria Finardi, BD, Filipppo Gagliardi, MD, Nicoletta Anzalone, MD, Alessandro Nonis, Roberto Furlan, MD, Piera Angelillo, MD, Marianna Sassone, MD, Daniela De Lorenzo, BD, Maria Rosa Terreni, MD, Marco Foppoli, Elena Guggiari, MD, Vittoria Tarantino, MD, Marika Eoli, MD, Fabio Ciceri, MD, Claudio Doglioni, Massimo Locatelli, MD, Maurilio Ponzoni, MD, Maria Giulia Cangi
Journal: Blood
Blood (2019) 134 (Supplement_1): 4114.
https://doi.org/10.1182/blood-2019-128298
Published: 2019
Journal Articles

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

Clinical Trials & Observations
Andrés J. M. Ferreri, Teresa Calimeri, Gian Marco Conte, Dario Cattaneo, Federico Fallanca, Maurilio Ponzoni, Eloise Scarano, Flavio Curnis, Alessandro Nonis, Paolo Lopedote, Giovanni Citterio, Letterio S. Politi, Marco Foppoli, Stefania Girlanda, Marianna Sassone, Salvatore Perrone, Caterina Cecchetti, Fabio Ciceri, Claudio Bordignon, Angelo Corti, Nicoletta Anzalone
Journal: Blood
Blood (2019) 134 (3): 252–262.
https://doi.org/10.1182/blood.2019000633
Published: 2019
Includes: Supplemental data
Journal Articles

R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial

Andres JM Ferreri, MD, Teresa Calimeri, MDPhD, Gian Marco Conte, MD, Dario Cattaneo, MD, Federico Fallanca, MD, Maurilio Ponzoni, MD, Eloise Scarano, Marianna Sassone, MD, Salvatore Perrone, MD, Caterina Cecchetti, MD, Paolo Lopedote, MD, Fiorella Ilariucci, Roberta Rudà, MD, Emanuele Angelucci, MD, Carlo Visco, Francesco Pisani, MD, Alberto Fabbri, MD, Luigi Petrucci, MD, Marco Bregni, MD, Dario Marino, MDPhD, Guido Gini, MD, Fabio Ciceri, MD, Angelo Corti, MD, Nicoletta Anzalone, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1687.
https://doi.org/10.1182/blood-2018-99-118507
Published: 2018
Journal Articles

Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis

Andres JM Ferreri, MD, Michele Reni, M.D., Marco Foppoli, M.D., Maurizio Martelli, M.D., Marina Siakantaris, M.D., Maurizio Frezzato, M.D., Maria Giuseppina Cabras, M.D., Alberto Fabbri, M.D., Gaetano Corazzelli, M.D., Fiorella Ilariucci, M.D., Giuseppe Rossi, M.D., Riccardo Soffietti, M.D., Caterina Stelitano, M.D., Daniele Vallisa, M.D., Francesco Zaja, M.D., Marta Gelemur, M.D., Gian Marco Aondio, M.D., Giuseppe Avvisati, M.D., Monica Balzarotti, MD, Alba Brandes, M.D., Maria Joao Costa, MD, Henry Gomez, M.D., Attilio Guarini, M.D., Graziella Pinotti, M.D., Luigi Rigacci, M.D., Catrina Uhlmann, M.D., Maria Angelopoulou, M.D., Maria Tirindelli, M.D., Virginia Naso, M.D., Alberto Franzin, M.D., Nicoletta Anzalone, M.D., Maurilio Ponzoni, M.D., Emanuele Zucca, M.D., Federico Caligaris- Cappio, M.D., Franco Cavalli, M.D.
Journal: Blood
Blood (2008) 112 (11): 580.
https://doi.org/10.1182/blood.V112.11.580.580
Published: 2008